Moreover, researchers have reported that bromodomain and extra-terminal (BET) bromodomain inhibition can mediate changes in expression at a genome-wide level in PRCA cells and increase the susceptibility of cancer cells to CD8 T cell targeting [30]. Here, CD8A is linked to cancer.